Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | GFER | P55789 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.96 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.62 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6689700 | 0.98 | GFER (1.00) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL429085 | 0.86 | MAPT (0.75) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL13912 | 0.86 | KMT2A (0.75) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL9382745 | 0.86 | MAPT (0.75) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL7302053 | 0.84 | MAPT (0.73) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL30620451 | 0.84 | MAPT (1.00) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL532005 | 0.84 | KMT2A (0.73) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL14829005 | 0.83 | MAPT (0.71) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL10683082 | 0.83 | KMT2A (0.71) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL14829004 | 0.83 | MAPT (0.71) | MAPTALDH1A1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034126-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3193604-B1 | SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS | EPIZYME INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-8440830-B2 | Tetrahydro-fused pyridines as histone deacetylase inhibitors | 4SC AG (DE) | 2013-05-14 | — | — | US | disclosed |
| EP-2197552-B1 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2197552-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009037001-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-03-26 | — | — | WO | disclosed |
| US-7183301-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2007-02-27 | — | — | US | disclosed |
| US-7160912-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR.REDDY'S LABORATORIES LTD. (IN) | 2007-01-09 | — | — | US | disclosed |
| US-20070004712-A1 | Salts of novel heterocyclic compounds having antibacterial activity | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC3 | MAPT 2144/4885ALDH1A1 912/4885KMT2A 86/4885 |
| US-20070004712-A1 | Salts of novel heterocyclic compounds having antibacterial activity | OXA1L, LSS, MRPL21 | MAPT 4373/4885ALDH1A1 1398/4885KMT2A 4439/4885 |
| US-20250034126-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | CBX2, CBX3, CBX6 | MAPT 4542/4885ALDH1A1 4418/4885KMT2A 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.